43 related articles for article (PubMed ID: 31749848)
1. Toxicity in patients treated with permanent prostate brachytherapy using intraoperatively built custom-linked seeds versus loose seeds.
Ollivier L; Lucia F; Nguyen T; Lucas C; Bourbonne V; Boussion N; Goasduff G; Fournier G; Pradier O; Dissaux G; Valeri A; Schick U
J Contemp Brachytherapy; 2020 Dec; 12(6):547-553. PubMed ID: 33437302
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.
Miyake M; Tanaka N; Asakawa I; Yamaki K; Inoue T; Suzuki S; Hori S; Nakai Y; Anai S; Torimoto K; Toritsuka M; Nakagawa H; Tsukamoto S; Fujii T; Ohbayashi C; Hasegawa M; Kasahara M; Fujimoto K
Contemp Clin Trials Commun; 2020 Sep; 19():100593. PubMed ID: 32637724
[TBL] [Abstract][Full Text] [Related]
3. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
4. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
5. Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.
Nakai Y; Tanaka N; Asakawa I; Torimoto K; Miyake M; Anai S; Fujii T; Hasegawa M; Fujimoto K
J Contemp Brachytherapy; 2019 Oct; 11(5):409-416. PubMed ID: 31749848
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
[TBL] [Abstract][Full Text] [Related]
7. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
[TBL] [Abstract][Full Text] [Related]
8. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
Nakai Y; Tanaka N; Asakawa I; Ohnishi K; Miyake M; Yamaki K; Torimoto K; Fujimoto K
Prostate; 2024 May; ():. PubMed ID: 38734992
[TBL] [Abstract][Full Text] [Related]
10. Biochemical control of the combination of cyclooxygenase-2 inhibitor and
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Morizawa Y; Hori S; Owari T; Fujii T; Ohbayashi C; Yamaki K; Hasegawa M; Fujimoto K
Int J Urol; 2020 Sep; 27(9):755-759. PubMed ID: 32588515
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Hori S; Morizawa Y; Tatsumi Y; Hasegawa M; Fujii T; Fujimoto K
J Radiat Res; 2019 Mar; 60(2):270-280. PubMed ID: 30576565
[TBL] [Abstract][Full Text] [Related]
12. Acute and late toxicities in localized prostate cancer patients treated with low-dose
Mukai Y; Hayashi N; Koike I; Kaizu H; Takano S; Sugiura M; Ito E; Sato M; Uemura H; Yao M; Hata M
J Contemp Brachytherapy; 2018 Oct; 10(5):397-404. PubMed ID: 30479615
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing long-term urinary symptoms after prostate brachytherapy.
Stone NN; Winoker JS; Kaplan SA; Stock RG
BJU Int; 2018 Nov; 122(5):831-836. PubMed ID: 29726091
[TBL] [Abstract][Full Text] [Related]
14. Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer.
Ghasemi A; Danesh B; Yazdani-Charati J; Hosseinimehr SJ
Antiinflamm Antiallergy Agents Med Chem; 2018; 17(1):57-67. PubMed ID: 29651970
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
